Monday, September 11, 2017                                       MRNS

 

 

 

MRNS - Paper trading

 

Analysis: Pharma company up hugely P/M. “Today announced that top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial”. Back in August the company reported good earnings (that is, less loss than expected/previous year) and had announced that they would most likely have good news for their Phase 2 trial evaluating in the upcoming quarter. Biggest % gainer this morning.

 

Entry: 4.75

 

Exit: 5.45ish. Goal is to make around 15%. So 5.45 would be best.

 

Comments: Stock up-trended nicely but did not reach the ideal target of 5.45 (15%).

 

Lesson: When stock turns around during the uptrend, it is imperative to take profits. I feel like there is another lesson to be drawn from the short sell side but for now I am 100% focused on going long. Next stepà Include SSS in recap